MYC is a clinically significant driver of mTOR inhibitor resistance in breast cancer.

J Exp Med · 2023 · PMC10465700 · PMID 37642941

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

We also observed a trend toward a higher prevalence of MYC amplification in the post-mTORi-treatment cohort versus the pretreatment cohort, although the difference did not reach statistical significance ( Fig. 9 C ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.